Researchers at the University of Missouri School of Medicine have shown in a mouse study that the powerful gene editing technique known as CRISPR may provide the means for lifelong correction of the genetic mutation, that causes a deficiency of dystrophin, responsible for the disorder. With more study, the researchers hope this cell-targeted CRISPR approach may one day lead to longlasting therapies for children with DMD